GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Therapeutics Inc (OTCPK:ARTH) » Definitions » Shares Buyback Ratio %

ARTH (Arch Therapeutics) Shares Buyback Ratio % : -245.81 (As of Dec. 13, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Arch Therapeutics Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Arch Therapeutics's current shares buyback ratio was -245.81%.


Arch Therapeutics Shares Buyback Ratio % Historical Data

The historical data trend for Arch Therapeutics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Therapeutics Shares Buyback Ratio % Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.59 -11.21 -22.62 -5.58 -275.25

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.83 -264.88 -1.13 6.28 -

Arch Therapeutics Shares Buyback Ratio % Calculation

Arch Therapeutics's Shares Buyback Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Sep. 2022 ) - Shares Outstanding (EOP) (A: Sep. 2023 )) / Shares Outstanding (EOP) (A: Sep. 2022 )
=(1.24968 - 4.68945) / 1.24968
=-275.25%

Arch Therapeutics's Shares Buyback Ratio for the quarter that ended in Jun. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2024 ) - Shares Outstanding (EOP) (A: Jun. 2024 )) / Shares Outstanding (EOP) (A: Mar. 2024 )
=(4.44436 - 4.44436) / 4.44436
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arch Therapeutics Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Arch Therapeutics's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
Executives
Terrence W Norchi director, officer: President & CEO C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
Michael S Abrams officer: CFO and Treasurer 64 RAMSHEAD ROAD, RAYNHAM MA 02767
Laurence Hicks director C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Guy L. Fish director C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Dan Yrigoyen officer: Vice President, Sales C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
James R Sulat director
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard E Davis officer: CFO & Treasurer
Avtar S Dhillon director C/O GENETRONICS INC, 11199 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Arthur L Rosenthal director 100 CYBERONICS BLVD., HOUSTON TX 77058
Alan Barber officer: Chief Financial Officer C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
William M Cotter officer: Chief Operating Officer C/O CLOSURE MEDICAL CORP, 5250 GREEN DAIRY RD, RALEIGH NC 27616